Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival

Leukemia & Lymphoma
R Hehlmann, H Heimpel

Abstract

One therapeutic concept in chronic myeloid leukemia (CML) assumes that a reduction of clonal genetically unstable cells also reduces the rate of secondary genetic changes and thereby postpones blast crisis. According to this concept, the degree of reduction of tumor burden should correlate with a prolongation of survival. The recent literature, in particular on controlled studies of IFN, hydroxyurea or intensive chemotherapy is reviewed and analyzed with regards to this concept. In chronic phase CML, intensity of treatment as determined by the degrees of WBC suppression, and, more recently, of cytogenetic remission, as measures of the reduction of tumor burden appear to correlate directly with survival. The superiority of a therapeutic regimen in chronic phase CML seems to primarily depend on whether its pharmacology permits a sufficiently high dosage to achieve the necessary reduction of tumor burden. The concept underlies present strategies that try to prolong survival in CML by IFN alone or in combination with intensive chemotherapy, by hydroxyurea, alone or in combination with IFN, and by high-dose chemotherapy followed by autografting.

References

Jul 15, 1987·Klinische Wochenschrift·L Müller, R Hehlmann
Feb 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianE J Freireich
May 1, 1983·American Journal of Physical Anthropology·C J UtermohleG M Heathcote
Jun 1, 1982·American Journal of Clinical Oncology·D RushingB J Kennedy
Mar 24, 1994·The New England Journal of Medicine·UNKNOWN Italian Cooperative Study Group on Chronic Myeloid LeukemiaMauro Fiacchini
Mar 24, 1994·The New England Journal of Medicine·J O Armitage
Aug 1, 1993·Annals of Hematology·M GriesshammerH Heimpel
Mar 4, 1993·The New England Journal of Medicine·N A KernanJ McCullough

❮ Previous
Next ❯

Citations

Aug 3, 2002·Leukemia & Lymphoma·Hana BruchovaRadim Brdicka
May 4, 2002·Best Practice & Research. Clinical Haematology·Andreas Hochhaus
Jun 6, 1998·Blood Cells, Molecules & Diseases·O M TrappP E Petrides
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rüdiger HehlmannSusanne Saussele
Aug 24, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·J ThieleH E Schaefer
Jun 19, 2007·Oncology Nursing Forum·Roxanna L Gapstur
Jun 2, 2012·Blood·Rüdiger Hehlmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.